Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | ITK | Q08881 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6476684 | 0.89 | HDAC1 (0.50) | HDAC1HDAC8PLK1 | |
| Hydrochloric Acid SCHEMBL6475673 | 0.79 | HDAC1 (0.46) | HDAC1HDAC8PLK1 | |
| Hydrochloric Acid SCHEMBL6475502 | 0.79 | HDAC1 (0.46) | HDAC1HDAC8PLK1 | |
| Hydrochloric Acid SCHEMBL6475557 | 0.77 | HDAC1 (0.46) | HDAC1HDAC8PLK1 | |
| SCHEMBL6980052 | 0.77 | F2 (0.50) | HDAC1HDAC8ITKBRD4CREBBP | |
| SCHEMBL6475825 | 0.76 | OPRM1 (0.49) | HDAC1HDAC8 | |
| SCHEMBL6475822 | 0.76 | OPRM1 (0.49) | HDAC1HDAC8 | |
| Hydrochloric Acid SCHEMBL6475787 | 0.75 | HDAC1 (0.44) | HDAC1HDAC8PLK1 | |
| SCHEMBL6480918 | 0.75 | POLB (0.43) | HDAC1ITKKCNH2 | |
| SCHEMBL6984235 | 0.73 | CNR2 (0.50) | HDAC1HDAC8ITKKCNH2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855713-B2 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | TPSAB1, PRSS3, TPSD1 | HDAC1 118/4885HDAC8 689/4885ITK 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.